Your Messages Inbox
Your Article Summary
See Latest ArticlesAllos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Allos Therapeutics, 08/11/09
Allos Therapeutics, Inc. announced that the Company has received notification from the U.S. Food and Drug Administration that the Oncologic Drugs Advisory Committee will hold a meeting on September 2009, to review the Company's New Drug Application for pralatrexate for the treatment of patients with relapsed or refractory peripheral T–cell lymphoma.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09
Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09
Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Bristol Myers-Squibb Company, 12/07/09
Article Search
Sponsor